ArticleJournal of experimental & clinical cancer research : CR2026
Soulangianolide A targets FAM120A to disrupt SREBP1-driven lipid metabolic reprogramming and suppress clear cell renal cell carcinoma.
Article in Journal of experimental & clinical cancer research : CR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundClear cell renal cell carcinoma (ccRCC) is characterized by extensive lipid metabolic reprogramming that drives tumor progression and therapeutic resistance. Although sterol regulatory element-binding protein 1 (SREBP1) is a central regulator of lipogenesis in ccRCC, the upstream mechanisms governing its activation remain poorly defined. Here, we investigated the role of FAM120A in SREBP1-dependent lipid metabolism and evaluated the therapeutic potential of the natural product Soulangianolide A (SA).
methodsStable knockdown of SREBP1 or FAM120A was established in ccRCC cells to assess lipid metabolism and malignant phenotypes. The antitumor activity and molecular mechanism of SA were investigated using integrated lipidomic, transcriptomic, proteomic, biochemical, and xenograft analyses, together with molecular docking, pull-down assays, surface plasmon resonance, and cellular thermal shift assays.
resultsGenetic depletion of SREBP1 suppressed lipogenic gene expression, intracellular lipid accumulation, and malignant phenotypes in ccRCC cells. FAM120A promoted SREBP1 nuclear accumulation and transcriptional activity, whereas SA inhibited SREBP1 signaling, reduced lipid storage, and induced apoptosis. Multi-omics analyses revealed extensive metabolic remodeling characterized by depletion of triglycerides and membrane lipids, accompanied by accumulation of ceramides and acylcarnitines, indicative of a lipotoxic state. Mechanistically, SA directly bound FAM120A at Cys531, disrupted the FAM120A-SREBP1 complex, impaired SREBP1 nuclear activity, and consequently attenuated lipid-dependent PPARγ signaling. In xenograft models, SA significantly suppressed tumor growth, reduced intratumoral lipid accumulation, inhibited SREBP1-driven lipogenic signaling, and potentiated the antitumor efficacy of MK-6482.
conclusionsOur findings identify the FAM120A-SREBP1-PPARγ axis as a critical driver of lipid metabolic reprogramming in ccRCC, establish FAM120A as a direct molecular target of SA, and demonstrate that pharmacological disruption of this pathway effectively suppresses tumor growth. These findings provide a mechanistic rationale for targeting lipid metabolic reprogramming in ccRCC and support SA as a promising metabolism-targeted therapeutic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.